“The
Report Colorectal Cancer Therapeutics in Major Developed Markets to
2020 - Increased Uptake of High Priced Drugs to Offset the Impact of
Generics provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz”
GBI Research, the leading
business intelligence provider, has released its latest research:
“Colorectal Cancer Therapeutics in Major Developed Markets to 2020
- Increased Uptake of High Priced Drugs to Offset the Impact of
Generics”, which provides in-depth analysis of the Colorectal
Cancer (CRC) therapeutics market in the eight major geographies of
the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The
report provides an estimation of the market size for 2013, along with
market forecast until 2020. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth pipeline analysis,
and deal analysis.
View Full Report at
http://www.marketresearchreports.biz/analysis/242389
The CRC therapeutics market in
the eight major markets is expected to grow at a Compound Annual
Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the
largest market share in 2013, equivalent to a global share of 44.1%,
followed by Japan and Germany with 14.7% and 11.9% respectively.
Spain had the lowest market share of the leading eight at 4.1%. All
markets covered in the report are expected to witness a slower growth
rate than Japan, which will grow at a CAGR of 5%. However, this
moderate growth will be stymied by the expected uptake of
lower-priced biosimilar versions of bevacizumab and cetuximab due to
the expiration of the patents of Avastin and Erbitux in the latter
half of the forecast period. Also expected is the launch of generic
versions of capecitabine, which will also affect the market. However,
this will be offset by the launch of premium-priced emerging
therapies. Stivarga is expected to be one of the biggest drivers of
growth in the CRC market, primarily due to its expected line
extension in the first-line metastatic setting as a maintenance
treatment for patients with resected liver metastases. The launch of
Lonsurf (TAS-102), approved in Japan in 2014, in the third- and
fourth-line settings will further increase the pharmacological
treatment rates in these lines, which will give patients a more
tolerable alternative to Stivarga. The moderate uptake of other
late-stage pipeline products, panitumumab and Xilonix, following
their expected approval, is expected to drive additional growth
within this market.
Download Detail Report With
Complete TOC at
http://www.marketresearchreports.biz/sample/sample/242389
The CRC pipeline is highly
robust, with potential drug candidates across various Phases of
clinical development. With nearly 400 active pipeline molecules, the
majority of the investigational drug candidates are being evaluated
for the treatment of CRC in advanced stages, either as first-line or
second-line therapies. The current investigational pipeline
candidates include new combination therapies and targeted therapies,
as well as promising immunotherapies and chemotherapy drug
candidates. As well as these active progressing pipeline molecules,
the pipeline also includes nearly 180 molecules that are either
inactive or discontinued.
Scope
The report analyzes treatment
usage patterns, market characterization, the pipeline, and key
licensing and co-development deals in the eight major markets: the
US, the UK, France, Germany, Spain, Italy, Japan and Canada. It
includes:
- A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
- Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006
Reasons
To Buy
The report will enhance your
decision-making capability by allowing you to:
- Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Colorectal Cancer
2.2 Symptoms
2.3 Epidemiology
2.4 Pathophysiology
2.4.1 Histology
2.4.2 Genetic Basis
2.4.3 Etiology of Colorectal
Cancer
2.5 Diagnosis
2.5.1 Digital Rectal
Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium
Enema
2.6 Prognosis and Disease
Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation
Therapy
2.7.2 Chemotherapy
2.7.3 Targeted Therapies
2.7.4 Resistance to
Pharmacological Therapies
2.7.5 Treatment Guidelines
2.8 GBI Research Report
Guidance
Related
Reports
GBI Research, a leading
business intelligence provider, has released its latest research
report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to
2020 - Off-patent Chemo-regimens to Retain Dominance Despite New
Launches”. The report provides estimates of the market size for
2013, along with forecasts until 2020 for the Asia-Pacific markets of
India, China, Australia and Japan. It also covers disease
epidemiology, treatment algorithms, treatment patterns, in-depth
analysis of clinical trials including failure rates and pipeline
analysis, and analysis of deals relevant to Ovarian Cancer (OC).
The report titled “The US
Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)”
provides an in-depth analysis of the United States chronic pain
therapy market (including medication, surgeries and therapies) with
detailed analysis of market sizing and growth and market share of the
various drugs involved in the treatment of chronic pain. The report
also assesses the key opportunities in the market and outlines the
factors that are and will be driving the growth of the industry.
Growth of the overall chronic pain therapy market has also been
forecasted for the period 2014-19, taking into consideration the
previous growth patterns, the growth drivers and the current and
future trends. Further, key players of the industry like Zogenix
Inc., Egalet Corporation and NektarTheropeutics are profiled.
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
E:
sales@marketresearchreports.biz
No comments:
Post a Comment